GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Shiller PE Ratio

KalVista Pharmaceuticals (STU:4XC1) Shiller PE Ratio : (As of May. 03, 2025)


View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


KalVista Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for KalVista Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Shiller PE Ratio Chart

KalVista Pharmaceuticals Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

KalVista Pharmaceuticals Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of KalVista Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, KalVista Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KalVista Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, KalVista Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where KalVista Pharmaceuticals's Shiller PE Ratio falls into.


;
;

KalVista Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

KalVista Pharmaceuticals's E10 for the quarter that ended in Jan. 2025 is calculated as:

For example, KalVista Pharmaceuticals's adjusted earnings per share data for the three months ended in Jan. 2025 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jan. 2025 (Change)*Current CPI (Jan. 2025)
=-0.889/134.0288*134.0288
=-0.889

Current CPI (Jan. 2025) = 134.0288.

KalVista Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201503 -4.399 99.621 -5.918
201506 -4.990 100.684 -6.643
201509 -2.370 100.392 -3.164
201512 -1.928 99.792 -2.589
201603 -3.143 100.470 -4.193
201606 -3.489 101.688 -4.599
201609 -1.123 101.861 -1.478
201701 -0.968 102.456 -1.266
201704 -0.401 103.167 -0.521
201707 -0.442 103.278 -0.574
201710 -0.426 104.070 -0.549
201801 -0.402 104.578 -0.515
201804 -0.050 105.708 -0.063
201807 -0.402 106.324 -0.507
201810 -0.191 106.695 -0.240
201901 -0.201 106.200 -0.254
201904 -0.436 107.818 -0.542
201907 -0.375 108.250 -0.464
201910 -0.298 108.577 -0.368
202001 -0.469 108.841 -0.578
202004 -0.340 108.173 -0.421
202007 -0.531 109.318 -0.651
202010 -0.493 109.861 -0.601
202101 -0.460 110.364 -0.559
202104 -0.543 112.673 -0.646
202107 -0.558 115.183 -0.649
202110 -0.690 116.696 -0.792
202201 -0.813 118.619 -0.919
202204 -0.907 121.978 -0.997
202207 -0.924 125.002 -0.991
202210 -0.913 125.734 -0.973
202301 -0.696 126.223 -0.739
202304 -0.702 127.992 -0.735
202307 -0.669 128.974 -0.695
202310 -0.758 129.810 -0.783
202401 -0.771 130.124 -0.794
202404 -0.997 132.289 -1.010
202407 -0.802 132.708 -0.810
202410 -0.835 133.182 -0.840
202501 -0.889 134.029 -0.889

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


KalVista Pharmaceuticals  (STU:4XC1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


KalVista Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


KalVista Pharmaceuticals Business Description

Traded in Other Exchanges
Address
55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals Headlines

No Headlines